Dameshghian Mahsa, Tafvizi Farzaneh, Tajabadi Ebrahimi Maryam, Hosseini Doust Reza
Department of Microbiology, Faculty of Advanced Science & Technology Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Biology, Parand Branch, Islamic Azad University, Parand, Iran.
Probiotics Antimicrob Proteins. 2024 May 17. doi: 10.1007/s12602-024-10288-2.
Breast cancer has emerged as the most widespread and dangerous type of malignancy among women worldwide. Postbiotics have recently emerged as a promising novel adjunct in breast cancer therapy, due to their immunomodulatory effects and the potential to mitigate the adverse effects of conventional treatments. This study aims to investigate the therapeutic effects of postbiotics derived from Lactobacillus brevis (CSF2) and Lactobacillus casei (CFS5), specifically examining their ability to inhibit cell proliferation and induce apoptosis in MCF-7 breast cancer cells. In the current study, the anticancer activity of the cell-free supernatant of L. brevis and L. casei was investigated against MCF-7 cells using MTT assay, flow cytometry, and qRT-PCR technique. Both bacteria showed a high potential for the induction of cell death in MCF-7 cells. However, CFS2 cytotoxicity was significantly higher than CFS5. Flow cytometry results showed significant induction of early apoptosis in cells treated with both CFS2 and CFS5 within 48 h. The induction was notably higher in cells treated with CFS2 compared to CFS5. Overall, CFS2 therapy resulted in a greater increase in BAX and CASP9 gene expression, as well as an elevated BAX/BCL2 ratio within 48 h. These findings indicate that the CFS2 treatment showed a higher level of apoptotic activity than the CFS5 treatment. High biocompatibility was demonstrated following treatment with CFS2 and CFS5. These CFSs may serve as adjunctive medications for suppressing the proliferation of cancer cells. The results of the current study highlight the potential of postbiotics in cancer treatment and suggest that supernatants may serve as effective agents for suppressing cancer cell growth and viability.
乳腺癌已成为全球女性中最普遍、最危险的恶性肿瘤类型。由于后生元具有免疫调节作用以及减轻传统治疗不良反应的潜力，它们最近已成为乳腺癌治疗中有前景的新型辅助手段。本研究旨在调查短乳杆菌（CSF2）和干酪乳杆菌（CFS5）产生的后生元的治疗效果，具体研究它们抑制MCF-7乳腺癌细胞增殖和诱导其凋亡的能力。在本研究中，使用MTT法、流式细胞术和qRT-PCR技术研究了短乳杆菌和干酪乳杆菌无细胞上清液对MCF-7细胞的抗癌活性。两种细菌都显示出诱导MCF-7细胞死亡的高潜力。然而，CFS2的细胞毒性明显高于CFS5。流式细胞术结果显示，用CFS2和CFS5处理的细胞在48小时内均显著诱导了早期凋亡。与CFS5处理的细胞相比，CFS2处理的细胞诱导作用明显更高。总体而言，CFS2处理在48小时内导致BAX和CASP9基因表达显著增加，以及BAX/BCL2比值升高。这些发现表明，CFS2处理显示出比CFS5处理更高水平的凋亡活性。用CFS2和CFS5处理后显示出高生物相容性。这些CFSs可作为抑制癌细胞增殖的辅助药物。本研究结果突出了后生元在癌症治疗中的潜力，并表明上清液可能是抑制癌细胞生长和活力的有效药物。
